16,424 Shares in IDEXX Laboratories, Inc. (IDXX) Acquired by Zurich Insurance Group Ltd FI
Zurich Insurance Group Ltd FI acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 16,424 shares of the company’s stock, valued at approximately $2,651,000.
Several other hedge funds have also recently bought and sold shares of IDXX. BlackRock Inc. raised its holdings in shares of IDEXX Laboratories by 1,967.1% in the 1st quarter. BlackRock Inc. now owns 6,427,027 shares of the company’s stock valued at $993,680,000 after buying an additional 6,116,102 shares during the period. Vanguard Group Inc. raised its holdings in shares of IDEXX Laboratories by 24.3% in the 1st quarter. Vanguard Group Inc. now owns 8,910,555 shares of the company’s stock valued at $1,377,660,000 after buying an additional 1,740,446 shares during the period. State Street Corp raised its holdings in shares of IDEXX Laboratories by 38.6% in the 1st quarter. State Street Corp now owns 3,911,739 shares of the company’s stock valued at $604,793,000 after buying an additional 1,089,880 shares during the period. Old Mutual Global Investors UK Ltd. purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $83,723,000. Finally, Renaissance Technologies LLC raised its holdings in shares of IDEXX Laboratories by 38.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after buying an additional 376,300 shares during the period. Hedge funds and other institutional investors own 87.64% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at 157.42 on Thursday. The firm’s 50-day moving average price is $155.53 and its 200 day moving average price is $159.66. The stock has a market cap of $13.74 billion, a P/E ratio of 54.15 and a beta of 0.48. IDEXX Laboratories, Inc. has a one year low of $102.45 and a one year high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The company had revenue of $508.90 million for the quarter, compared to analyst estimates of $502.44 million. During the same period last year, the company posted $0.74 earnings per share. The firm’s revenue was up 9.1% compared to the same quarter last year. Equities research analysts expect that IDEXX Laboratories, Inc. will post $3.18 EPS for the current fiscal year.
In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 13,000 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at $157,429,886.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence D. Kingsley acquired 2,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was bought at an average cost of $151.76 per share, for a total transaction of $303,520.00. Following the completion of the transaction, the director now directly owns 3,344 shares of the company’s stock, valued at $507,485.44. The disclosure for this purchase can be found here. Insiders sold 151,734 shares of company stock worth $23,436,626 over the last three months. 2.77% of the stock is currently owned by corporate insiders.
Several equities research analysts recently issued reports on the company. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Friday, July 14th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price objective on the stock in a report on Wednesday, July 19th. CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target on the stock in a report on Friday, July 28th. Finally, Canaccord Genuity restated a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Tuesday, June 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Hold” and an average target price of $174.00.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.